Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers
Conditions
Interventions
IRL201104
Placebo
Locations
1
United States
Revolo Phase I site
Los Angeles, California, United States
Start Date
May 26, 2023
Primary Completion Date
September 12, 2023
Completion Date
September 12, 2023
Last Updated
September 28, 2023
NCT00104325
NCT07118891
NCT03878121
NCT01399385
NCT07295717
NCT03807401
Lead Sponsor
Revolo Biotherapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions